ClinicalTrials.gg
Not yet recruitingNCT07928258Updated Nov 10, 2026

A Study of LY4336619 in Adult Participants With Advanced Solid Tumors

A Phase 1 interventional study of LY4336619 and Sofetabart Mipitecan (Sofe-M) in Endometrial Neoplasms, Ovarian Neoplasms and Neoplasms, Germ Cell and Embryonal, sponsored by Eli Lilly and Company. Not yet recruiting at 23 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Updated Nov 10, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
370
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Endometrial Neoplasms by Eli Lilly and Company — 4 open to participants now, 8 under way, none of them phase 3. Endometrial Neoplasms · Eli Lilly and Company.

Planned enrollment
7th of 10
370 · median 400
Started
2026
the only one that year
Phase 1
6 of 11
3 open now
Registered
11th of 11
by date

Among the 11 studies in Endometrial Neoplasms by Eli Lilly and Company, this one is the 7th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2026, is one of 6 in phase 1, and was the 11th registered.

Endometrial Neoplasms

1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

4 of the 11 studies in Endometrial Neoplasms by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Endometrial Neoplasms by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate how safe and effective LY4336619 is in adults with advanced cancer. Some participants will receive LY4336619 alone, and some will receive it with another cancer medicine. Participants will be in the study for up to 2 years, depending on how they tolerate and respond to treatment.

03

Conditions studied

  • Endometrial Neoplasms
  • Ovarian Neoplasms
  • Neoplasms, Germ Cell and Embryonal
  • Carcinoma, Non-Small-Cell Lung
  • Stomach Neoplasms
  • Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have histological diagnosis of locally advanced or solid tumor .
  • Have a of at least 12 weeks as judged by the investigator.
  • Must be an appropriate candidate for study treatment. Study treatment is considered appropriate where approved measures are no longer effective or are not considered appropriate or safe in the opinion of the investigator, or the individual refuses the remaining most appropriate standard of care treatment.
  • Have a performance status of 0 or 1 on the (ECOG) scale or performance status of at least 80%.

Exclusion criteria

Exclusion Criteria:

  • Has a known or suspected history of active central nervous system (CNS) involvement.
  • Has a history of carcinomatous meningitis.
  • Current or history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease.
  • Residual symptoms of neurotoxicity from prior chimeric antigen receptor-modified T cell (CAR-T) or bispecifics.
  • Has significant cardiovascular disease
  • Has an active uncontrolled systemic bacterial, viral, fungal, or parasitic infection (except for fungal nail infection), or other active disease process which, in the opinion of the investigator and the sponsor, makes it undesirable for the individual to participate in the trial. Screening for chronic conditions is not required.
  • Has any unresolved toxicities from prior therapy greater than National Cancer Institute (NCI) (CTCAE) v6.0 Grade 1 at the time of starting study treatment except for alopecia, endocrine adverse events (AEs) on replacement therapy, and Grade 2 neuropathy.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
370 participants (estimated)

Study arms

  • Experimental
    LY4336619 Dose Escalation

    Escalating doses of LY4336619 administered intravenously (IV)

    Drug: LY4336619

  • Experimental
    LY4336619 Dose Optimization

    Comparing 2 or more doses (evaluated during dose escalation) of LY4336619 administered IV

    Drug: LY4336619

  • Experimental
    LY4336619 and Sofetabart Mipitecan (Sofe-M) Combination

    Comparing LY4336619 in combination with Sofe-M administered IV

    Drug: LY4336619 · Drug: Sofetabart Mipitecan (Sofe-M)

  • Experimental
    LY4336619 Dose Expansion

    LY4336619 administered IV

    Drug: LY4336619

Interventions

  • DrugLY4336619

    Administered IV

  • DrugSofetabart Mipitecan (Sofe-M)

    Administered IV

06

What researchers measure

Primary outcomes

  1. Number of Participants with Dose-Limiting Toxicities (DLTs)

    Time frame: From Cycle 1 Day 1 through Cycle 2 Day 1 (approximately 21 days)

  2. Objective Response Rate (ORR) of LY4336619 in the Dose Expansion Arms

    Investigator-assessed ORR per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Pharmacokinetics (PK) of LY4336619: Maximum Concentration (Cmax)

    Time frame: Up to approximately 2 years

  2. PK of LY4336619: Area under the Concentration-time Curve (AUC)

    Time frame: Up to approximately 2 years

  3. PK of Sofe-M in the Combination Cohorts: Cmax

    Time frame: Up to approximately 2 years

  4. PK of Sofe-M in the Combination Cohorts: AUC

    Time frame: Up to approximately 2 years

  5. ORR of LY4336619

    Investigator assessed per RECIST v1.1.

    Time frame: Up to approximately 2 years

  6. Duration of Response (DOR) of LY4336619

    Per RECIST v1.1.

    Time frame: Up to approximately 2 years

  7. Time to Response (TTR) of LY4336619

    Per RECIST v1.1.

    Time frame: Up to approximately 2 years

  8. Progression-Free Survival (PFS) of LY4336619

    Per RECIST v1.1.

    Time frame: Up to approximately 2 years

  9. Disease Control Rate (DCR) of LY4336619

    Per RECIST v1.1.

    Time frame: Up to approximately 2 years

07

Study locations

23 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Mar 2032, 63 months later.

Of 88 industry-sponsored phase 1 interventional studies under Endometrial Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 69. This study's planned 63 months is above that.

Counting every sponsor, half of 131 studies reached it within 61 months; a quarter within 46 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2026
First posted
Nov 10, 2026
StartEst.
Dec 2026
Primary completionEst.
Mar 2032
CompletionEst.
Mar 2032
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07928258
Responsible party
Sponsor
First posted
Nov 10, 2026
Start date
Dec 2026 (estimated)
Primary completion
Mar 2032 (estimated)
Completion
Mar 2032 (estimated)
Last update
Nov 10, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion